Advertisement
Organisation › Details
Celltrion (Group)
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for Inflectra® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. Also Celltrion received FDA and EC’s approval for Truxima® and Herzuma®. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Beyond antibody biosimilars, Celltrion is actively engaged in licensing in/out through strategic partnerships with the industry, academia, and research centres to expand its pipelines. Through these partnerships, Celltrion plans to boost the effectiveness of new drug R&D projects and revitalize the bio ecosystems in and outside of Korea. *
Start | 2002-01-01 established | |
Today | Celltrion Inc. (KRX: 068270) | |
Industry | contract manufacturing (drugs) | |
Industry 2 | contract manufacturing (biologicals) | |
Person | Kee, Woo Sung (Celltrion 201707 CEO) | |
Street | Song-do New-city, 13-6, SongDo-Dong, Yeonsu-gu | |
City | 406-130 Incheon | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2007-11-28) |
* Document for »About Section«: Iksuda Therapeutics Ltd.. (6/7/21). "Press Release: Iksuda Therapeutics Closes $47 Million Financing Round". Newcastle. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Celltrion (Group)
- [1] Celltrion, Inc.. (2/14/18). "Press Release: Celltrion Receives EU Approval for Trastuzumab Biosimilar". Incheon....
- [2] Teva Pharmaceutical Industries Ltd.. (8/3/17). "Press Relase: Teva Reports Second Quarter 2017 Financial Results". Jerusalem....
- [3] Teva Pharmaceutical Industries Ltd.. (7/31/17). "Press Relase: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin (trastuzumab)". Incheon & Jerusalem....
- [4] Teva Pharmaceutical Industries Ltd.. (6/29/17). "Press Release: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan (rituximab)". Incheon & Jerusalem....
- [5] Mundipharma International Ltd.. (6/14/17). "Press Release: New Data Show Truxima (CT-P10) to Have Comparable Efficacy and Tolerability in Advanced Follicular Lymphoma to Reference i.v. Rituximab". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top